Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions

Our plain-English summary of Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions, by R.M. Wong (Journal of Thoracic Oncology, 2016).

The study

• Author: R.M. Wong
• Journal: Journal of Thoracic Oncology
• Published: 2016;11(10):1602-3
• Type of article: Editorial
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

In plain English

This article is a two-page editorial, not a study. It reported no new data and did not discuss asbestos. It commented on two recent articles by Lievense et al. and Chéné et al. about malignant pleural mesothelioma (MPM). The author noted that fluid collecting around the lung in MPM (pleural effusions) has been found, in earlier work, to contain proteins that may suppress the body's immune response to the tumor. Examples include transforming growth factor beta and interleukin-10. The author pointed out that, according to other research, blocking a single factor such as transforming growth factor beta had not produced strong evidence of clinical benefit in MPM patients. The author argued that combining treatments aimed at several factors may be a rational strategy. The author suggested that the space around the lung may be the best place to deliver immunotherapy for this disease. The author also called for more detailed study of DNA repair defects in MPM, including mismatch repair. The author cited a recent small trial, focused mainly on colorectal cancer, in which a defect in DNA mismatch repair appeared to predict response to PD-1 blockade immunotherapy. The author suggested that such studies in MPM could potentially reveal markers to guide treatment.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: editorial (commentary on other published articles; no original data)
• The authors' conclusion: The author suggested that blocking multiple immunosuppressive factors is likely needed for immunotherapy to work best in MPM. The author also suggested that the intrapleural space may be the optimal site for treatment, and that DNA repair defects in MPM, including mismatch repair, deserve more detailed analysis as possible biomarkers.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Biomarker.

Related studies

• Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model — J.M. Porcel, A. Esquerda, et al. (2016)
• Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis — H. Suzuki, K. Asami, et al. (2014)
• Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study — R. Thomas, F. Piccolo, et al. (2015)
• Subcutaneous seeding after ultrasound-guided placement of intrapleural catheter. An unusual complication of the intracavitary palliative treatment of pleural mesothelioma — S. Sartori, I. Nielsen, et al. (1999)
• Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review — R. Tozzoli, S.M. Basso, et al. (2016)
• Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma — M.J. McCoy, A.K. Nowak, et al. (2009)

Browse more research in Journal of Thoracic Oncology, or return to medical research.